Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Solid Tumor, Adult 1Pyloric Stenosis, Hypertrophic 1Nasopharyngeal Carcinoma 1Lymphoproliferative Disorders 1Epstein-Barr Virus Infections 1EBV Lymphomas 1Advanced Cancer 1

Interventions

Rituximab 4Tacrolimus 3fludarabine 2cobomarsen 2Peripheral Blood Stem Cell Transplantation 2Ganciclovir 2Etoposide 2Cyclophosphamide 2Busulfan 2Antilymphocyte Serum 2ruxolitinib 1ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine phosphate 1ferric carboxymaltose 1epratuzumab 1denileukin diftitox 1dacetuzumab 1beta-Glucans 1arginine butyrate 1Vorinostat 1Vincristine 1Valganciclovir 1Stem Cell Transplantation 1Sirolimus 1Prednisone 1Oxycodone 1Mycophenolic Acid 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphoproliferative Disorders × Valganciclovir × Clear all
NCT00992732 2011-08-01

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡